Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B3 | P37058 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androsterone SCHEMBL10273502 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL269982 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL13175783 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Epiandrosterone SCHEMBL295167 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL12811704 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15426610 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL23031469 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL19750468 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL21114416 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15963588 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-07-14 | — | — | US | disclosed |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| WO-2010060215-A1 | 2-(N-SUBSTITUTED PIPERAZINYL) STEROID DERIVATIVES | UNIVERSITé LAVAL (CA) | 2010-06-03 | — | — | WO | disclosed |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-06-03 | — | — | US | disclosed |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-06-03 | — | — | US | disclosed |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-11-13 | — | — | US | disclosed |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036320-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP17A1, HSD17B1, HSD17B7 | G6PD 3160/4885GPBAR1 327/4885LMNA 4503/4885 |
| US-20100137269-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, CYP21A2, HSD17B1 | G6PD 2722/4885GPBAR1 425/4885LMNA 4195/4885 |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, CYP21A2 | G6PD 3060/4885GPBAR1 326/4885LMNA 4511/4885 |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | NR5A1, HSD17B11, CYP17A1 | G6PD 1480/4885GPBAR1 400/4885LMNA 2805/4885 |
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | AR, SHBG, NCOA1 | G6PD 2070/4885GPBAR1 158/4885LMNA 2069/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | G6PD 3491/4885GPBAR1 757/4885LMNA 2135/4885 |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | G6PD 416/4885GPBAR1 221/4885LMNA 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.